Ocugen Inc (OCGN)vsRegeneron Pharmaceuticals Inc (REGN)
OCGN
Ocugen Inc
$1.95
+1.56%
HEALTHCARE · Cap: $688.58M
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 324915% more annual revenue ($14.34B vs $4.41M). REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).
OCGN
Hold36
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for OCGN.
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 85.6%
Revenue surging 54.2% year-over-year
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -7.8% — below average capital efficiency
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : OCGN
The strongest argument for OCGN centers on Operating Margin, Revenue Growth. Revenue growth of 54.2% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : OCGN
The primary concerns for OCGN are EPS Growth, Market Cap, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
OCGN profiles as a hypergrowth stock while REGN is a value play — different risk/reward profiles.
OCGN carries more volatility with a beta of 2.90 — expect wider price swings.
OCGN is growing revenue faster at 54.2% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 36/100), backed by strong 31.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ocugen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?